Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819511 | 0.91 | SIGMAR1 (0.36) | CHRM1SIGMAR1L3MBTL1MCHR1CCR3 | |
| SCHEMBL3602537 | 0.83 | SIGMAR1 (0.35) | SIGMAR1L3MBTL1MCHR1CCR3KMT2A | |
| SCHEMBL3607054 | 0.83 | KDM1A (0.32) | — | |
| SCHEMBL3604795 | 0.76 | CDK4 (0.37) | — | |
| SCHEMBL3730946 | 0.75 | CCR1 (0.35) | CHRM1SIGMAR1L3MBTL1MCHR1KMT2A | |
| SCHEMBL922023 | 0.74 | SIGMAR1 (0.40) | CHRM1SIGMAR1L3MBTL1MCHR1CCR3 | |
| SCHEMBL3155543 | 0.74 | SLC2A1 (0.54) | SIGMAR1L3MBTL1MCHR1 | |
| SCHEMBL3616104 | 0.74 | KCNH2 (0.57) | — | |
| SCHEMBL3323992 | 0.73 | TOP2A (0.40) | CHRM1SIGMAR1L3MBTL1MCHR1KMT2A | |
| SCHEMBL3328189 | 0.73 | TOP2A (0.40) | CHRM1SIGMAR1L3MBTL1MCHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | CHRM1 4316/4885SIGMAR1 211/4885L3MBTL1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.